Purpose: Our preclinical studies demonstrated the potential of chimeric antigen receptor (CAR)-glypican-3 (GPC3) T-cell therapy for hepatocellular carcinoma (HCC). We report herein the first published results of CAR-GPC3 T-cell therapy for HCC. Materials and Methods: In two prospective phase 1 studies, adult patients with advanced GPC3+ HCC (Child-Pugh A) received autologous CAR-GPC3 T-cell therapy following cyclophosphamide- and fludarabine-induced lymphodepletion. The primary objective was to...
Tue May 05, 2020 15:57
Purpose: In NSABP B-41, pathologic complete response (pCR) was associated with prolonged survival among women with HER2-positive operable breast cancer treated with neoadjuvant chemotherapy and lapatinib, trastuzumab, or the combination. We used a large human breast cancer gene expression panel to select candidate prognostic biomarkers for pCR among women treated with trastuzumab in NSABP B-41. Experimental Design: Eligible patients had a baseline pre-adjuvant treatment core biopsy sample, known...
Tue May 05, 2020 15:57
Purpose: After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors of response to sorafenibfor hepatocellular carcinoma (HCC).On the basis of the results of our two retrospective studies, we designed the multicenter INNOVATE study with the aim to validate the role of NOS3 and ANGPT2 polymorphisms in HCC patients treated with sorafenib [NCT02786342]. Experimental Design: This prospective multicenter study was conducted at 10 centres in...
Tue May 05, 2020 15:57
Purpose: Although cisplatin plus radiotherapy is a standard treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC), cisplatin contraindication is common. Radiation elicits and promotes tumor-directed immune-stimulation, which may potentiate anti-PD-1 therapy. We provide the first efficacy report of combined pembrolizumab and definitive radiotherapy in LA-HNSCC. Experimental Design: This single-arm, multi-institution, phase II study (NCT02609503) enrolled 29 cisplatin ineligible...
Tue May 05, 2020 15:57
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου